Bloomfield Frank H, van Zijl Pierre L, Bauer Michael K, Harding Jane E
Liggins Institute, University of Auckland, PB 92019, Auckland, New Zealand.
J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):287-97. doi: 10.1097/00005176-200209000-00010.
To investigate, in the late-gestation ovine fetus: 1) amino acid concentrations in blood and amniotic fluid, 2) the effects of intrauterine growth restriction (IUGR) induced by placental embolization on these concentrations, 3) fetal gut uptake of glutamine in healthy and IUGR fetuses, and 4) the effects of intraamniotic insulin-like growth factor-I (IGF-1) treatment on these parameters.
Fetuses were randomly assigned to control (n = 9), IUGR + saline (n = 9), or IUGR + IGF-1 (n = 11) groups. IUGR was induced by uteroplacental embolization from 114 to 119 days (term = 145 days). IUGR fetuses received daily intraamniotic injections of saline or IGF-1 (20 microg/d) from 120 to 130 days.
Baseline amino acid concentration was higher in fetal blood than amniotic fluid for all essential amino acids except lysine and histidine, but was lower for serine, alanine, and methylhistidine. Embolization reduced total amino acid concentration in blood and amniotic fluid by approximately 15%. Concentrations were reduced for serine, glutamine, and methylhistidine in blood and for serine in amniotic fluid, but were increased for glycine, alanine, and asparagine in blood and for alanine in amniotic fluid. Glutamine was taken up by the fetal gut (glutamine:oxygen quotient of 0.65) and citrulline was released by the gut. IGF-1 treatment did not alter amino acid concentration in blood or amniotic fluid, but reduced gut uptake of glutamine from blood and the gut glutamine:oxygen quotient by 15%. Citrulline release was unchanged.
These data suggest that amniotic fluid amino acids are not simply filtered from fetal blood and may provide an important pool of nutrients for the fetus. They demonstrate for the first time that glutamine is taken up by the fetal gut. IGF-1 treatment may promote gut utilization of amino acids from the amniotic fluid pool.
在妊娠晚期绵羊胎儿中研究:1)血液和羊水中的氨基酸浓度;2)胎盘栓塞诱导的宫内生长受限(IUGR)对这些浓度的影响;3)健康和IUGR胎儿肠道对谷氨酰胺的摄取;4)羊膜腔内胰岛素样生长因子-I(IGF-1)治疗对这些参数的影响。
将胎儿随机分为对照组(n = 9)、IUGR + 生理盐水组(n = 9)或IUGR + IGF-1组(n = 11)。在妊娠114至119天(足月为145天)通过子宫胎盘栓塞诱导IUGR。IUGR胎儿在妊娠120至130天每天接受羊膜腔内注射生理盐水或IGF-1(20微克/天)。
除赖氨酸和组氨酸外,所有必需氨基酸在胎儿血液中的基线氨基酸浓度均高于羊水,但丝氨酸、丙氨酸和甲基组氨酸的浓度则较低。栓塞使血液和羊水中的总氨基酸浓度降低了约15%。血液中的丝氨酸、谷氨酰胺和甲基组氨酸以及羊水中的丝氨酸浓度降低,但血液中的甘氨酸、丙氨酸和天冬酰胺以及羊水中的丙氨酸浓度升高。胎儿肠道摄取谷氨酰胺(谷氨酰胺:氧商为0.65),并释放瓜氨酸。IGF-1治疗未改变血液或羊水中的氨基酸浓度,但使肠道从血液中摄取谷氨酰胺以及肠道谷氨酰胺:氧商降低了15%。瓜氨酸释放未改变。
这些数据表明,羊水氨基酸并非简单地从胎儿血液中滤过,可能为胎儿提供重要的营养库。它们首次证明胎儿肠道摄取谷氨酰胺。IGF-1治疗可能促进肠道利用羊水中的氨基酸库。